Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

BACKGROUND: EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. ME...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Waddell, Tom, Chau, Ian, Cunningham, David, Gonzalez, David, Okines, Alicia Frances Clare, Wotherspoon, Andrew, Saffery, Claire, Middleton, Gary, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom, Coxon, Fareeda, Smith, David, Waters, Justin, Iveson, Timothy, Falk, Stephen, Slater, Sarah, Peckitt, Clare, Barbachano, Yolanda
Format: Artigo
Sprog:Inglês
Udgivet: Lancet Pub. Group 2013
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3669518/
https://ncbi.nlm.nih.gov/pubmed/23594787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70096-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker